This cluster groups 2 independently calculated changes: Cash & equivalents decreased 70.0%; Operating cash flow decreased 9.0%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTSenti Biosciences Holdings, Inc.'s latest supported as-filed period reports revenue of $17,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 70.0%; Operating cash flow decreased 9.0%.
2 evidence-backed componentsCurrent liabilities changed +57.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SNTI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-067624SEC ↗8-KOct 26, 2026Period Oct 21, 20260001140361-26-040772SEC ↗4Oct 23, 2026Period Oct 21, 20260001628280-26-067085SEC ↗4Oct 23, 2026Period Oct 21, 20260001628280-26-067084SEC ↗8-KOct 15, 2026Period Oct 15, 20260001628280-26-065992SEC ↗8-KOct 13, 2026Period Oct 8, 20260001628280-26-065685SEC ↗8-KSep 24, 2026Period Sep 23, 20260001628280-26-063369SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 21, 2026Filed Oct 23, 2026 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Tax WithholdingDirect | 19,953 | $0 | $0 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Lu Timothy KCEO | Tax WithholdingDirect | 157,312 | $0 | $0 | Form 4 ↗ |
| Mar 9, 2026Filed Mar 11, 2026 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Tax WithholdingDirect | 10,757 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Working capital / assets changed -4121 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash & equivalents changed -70.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Total assets changed -51.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Working capital changed -112.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change.
Research & development changed -22.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current ratio changed -74.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-060600